T. Rowe Price Associates’s Sanara MedTech SMTI Stock Holding History

T. Rowe Price Associates’s Portfolio SMTI Stock Details SMTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$188K	Buy	10,898 +2,200	+25%	+$45.3K	﹤0.01%	2864
2025 Q4	$204K	Buy	8,698 +2,100	+32%	+$54.2K	﹤0.01%	2801
2025 Q3	$210K	Buy	+6,598	New	+$199K	﹤0.01%	2776
2025 Q1	–	Sell	-6,237	Closed	-$208K	–	3072
2024 Q4	$208K	Buy	+6,237	New	+$212K	﹤0.01%	2665
2024 Q2	–	Sell	-5,805	Closed	-$215K	–	3020
2024 Q1	$215K	Buy	5,805 +322	+6%	+$12K	﹤0.01%	2589
2023 Q4	$226K	Buy	+5,483	New	+$176K	﹤0.01%	2489
2023 Q3	–	Sell	-5,371	Closed	-$216K	–	2910
2023 Q2	$216K	Buy	+5,371	New	+$220K	﹤0.01%	2500
2023 Q1	–	Sell	-5,900	Closed	-$268K	–	2948
2022 Q4	$268K	Buy	+5,900	New	+$203K	﹤0.01%	2412

Other funds holding SMTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SWM

Stonebridge Wealth Management Oak Brook, Illinois $112M AUM 23.07% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

T. Rowe Price Associates's SMTI Position: Q1 2026 in Review

T. Rowe Price Associates increased its Sanara MedTech (SMTI) stake by 25% in Q1 2026, buying an estimated $45.3K and bringing the position to 10,898 shares worth $188K. The position accounts for ﹤0.01% of the portfolio, ranked #2864.

T. Rowe Price Associates first reported a position in SMTI in Q4 2022 and has held it in 8 quarters since. The position peaked at $268K in Q4 2022. 65 funds tracked by Wall St. Rank hold SMTI as of Q1 2026.

T. Rowe Price Associates held 10,898 shares of Sanara MedTech worth $188K as of Q1 2026.
T. Rowe Price Associates bought 2,200 Sanara MedTech shares in Q1 2026, an estimated $45.3K.
Sanara MedTech made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2864 holding.
T. Rowe Price Associates first reported a position in Sanara MedTech in Q4 2022 and has held it in 8 quarters since.
T. Rowe Price Associates's Sanara MedTech position peaked at $268K in Q4 2022.
65 funds tracked by Wall St. Rank held Sanara MedTech as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.